Omnicell Inc (Omnicell) develops and implements advanced medication management solutions, including robotics, software workflows, and expert services. It provides solutions across various care settings, including inpatient, outpatient, and retail environments, with an emphasis on improving clinical, operational, and financial outcomes. Omnicell's product and service portfolio includes a range of medication and supply dispensing systems, central pharmacy automation solutions, patient engagement solutions, and inventory optimization services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Omnicell's R&D arm focus on collaborating with customers to develop solutions that address unmet needs and challenges. The company invests significantly in enhancing the XT Series automated dispensing systems through hardware and software upgrades. Substantial investments are also made to help customers transition to a cloud-based platform, supporting the vision of the Autonomous Pharmacy. This includes developing technology-enabled software and services, enhancing SaaS and Expert Services offerings, and building scalable software solutions. The company is advancing its robotic automation capabilities and migrating solutions to OmniSphere, a cloud-native software workflow engine and data platform designed to integrate enterprise robotics and smart devices across medication management. In FY2025, the company incurred expenses of US$88.6 million on R&D, which as a percentage of revenue, stood at 7%.